Medpace Stock Price, News & Analysis (NASDAQ:MEDP)

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings Inc (NASDAQ:MEDP) issued its quarterly earnings data on Monday, July, 29th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.63 by $0.18. The firm earned $214.10 million during the quarter, compared to analysts' expectations of $200.99 million. Medpace had a net margin of 11.28% and a return on equity of 17.65%. The business's revenue was up 25.8% on a year-over-year basis. During the same period last year, the company earned $0.61 earnings per share. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, October 28th 2019. View Earnings Estimates for Medpace.

Medpace will be holding an earnings conference call on Monday, October 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Medpace updated its FY19 earnings guidance on Monday, July, 29th. The company provided earnings per share (EPS) guidance of $2.83-2.93 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.65. The company issued revenue guidance of $840-860 million, compared to the consensus revenue estimate of $827.58 million.

4 analysts have issued 1-year price targets for Medpace's stock. Their predictions range from $62.00 to $85.00. On average, they expect Medpace's share price to reach $74.67 in the next twelve months. This suggests that the stock has a possible downside of 0.0%. View Analyst Price Targets for Medpace.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Medpace in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Medpace.

Media headlines about MEDP stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Medpace earned a coverage optimism score of 0.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Medpace.

Medpace saw a decline in short interest during the month of September. As of September 15th, there was short interest totalling 2,320,000 shares, a decline of 12.8% from the August 15th total of 2,660,000 shares. Based on an average trading volume of 407,200 shares, the short-interest ratio is currently 5.7 days. Currently, 8.5% of the shares of the stock are sold short. View Medpace's Current Options Chain.

Some companies that are related to Medpace include Icon (ICLR), PRA Health Sciences (PRAH), Charles River Laboratories Intl. (CRL), Syneos Health (SYNH), Exelixis (EXEL), BTG (BTGGF), National Research (NRC), Intrexon (XON), Auxly Cannabis Group (CBWTF), STARPHARMA HOLD/S (SPHRY), Sorrento Therapeutics (SRNE), Luna Innovations (LUNA), Pieris Pharmaceuticals (PIRS), Anavex Life Sciences (AVXL) and Eloxx Pharmaceuticals (ELOX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Medpace investors own include EXACT Sciences (EXAS), NVIDIA (NVDA), Alibaba Group (BABA), BioTelemetry (BEAT), Paypal (PYPL), Square (SQ), Intuitive Surgical (ISRG), Okta (OKTA), Paycom Software (PAYC) and ABIOMED (ABMD).

(MEDP) raised $150 million in an initial public offering on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities served as the underwriters for the IPO and Baird and William Blair were co-managers.

Medpace's stock is owned by a number of of retail and institutional investors. Top institutional investors include Tributary Capital Management LLC (0.54%), Scout Investments Inc. (0.27%), Rhumbline Advisers (0.23%), State of New Jersey Common Pension Fund D (0.10%), Alberta Investment Management Corp (0.07%) and Envestnet Asset Management Inc. (0.07%). Company insiders that own Medpace stock include August J Troendle, Jesse J Geiger, Medpace Investors, Llc, Medpace Limited Partnership and Stephen P Ewald. View Institutional Ownership Trends for Medpace.

MEDP stock was sold by a variety of institutional investors in the last quarter, including Virginia Retirement Systems ET AL, Convergence Investment Partners LLC, Scout Investments Inc., Tributary Capital Management LLC, Strs Ohio, Optimum Investment Advisors, Bowling Portfolio Management LLC and Envestnet Asset Management Inc.. Company insiders that have sold Medpace company stock in the last year include August J Troendle, Jesse J Geiger, Medpace Investors, Llc and Stephen P Ewald. View Insider Buying and Selling for Medpace.

MEDP stock was purchased by a variety of institutional investors in the last quarter, including State of New Jersey Common Pension Fund D, Alberta Investment Management Corp, CIBC Private Wealth Group LLC, State of Alaska Department of Revenue, Assenagon Asset Management S.A., Navellier & Associates Inc, Avitas Wealth Management LLC and Rhumbline Advisers. View Insider Buying and Selling for Medpace.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $74.69.

Medpace has a market capitalization of $2.68 billion and generates $704.59 million in revenue each year. The company earns $73.18 million in net income (profit) each year or $2.59 on an earnings per share basis. Medpace employs 2,900 workers across the globe.View Additional Information About Medpace.

The official website for Medpace is http://www.medpace.com/.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]